The company said sales of its MyPRS test for myeloma risk increased during the quarter, but full-year 2015 revenues fell because of increased R&D costs.
Researchers identified a germline variant on chromosome 6 that corresponded to overall survival times in multiple myeloma patients from four study cohorts.
The study will evaluate Signal's MyPRS test for stratifying patients at risk of developing symptomatic multiple myeloma.
The genetic test determines risk levels and prognosis for patients with multiple myeloma based on the SKY92 gene signature.
The deals with Stratose, USA Managed Care Organization, and Evolutions Health Systems provides covered access to the test to more than 21 million patients.
NIH researchers have uncovered a blood-based microRNA signature that may be able to tell which patients with precursor disease may progress to myeloma.
The partners will run several studies to validate the use of the MyPRS test in informing disease management in patients with multiple myeloma and its precursors.
As part of the Myeloma XI trial, a UK-led team used exome sequencing on 463 individuals with myeloma to look for mutations related to survival patterns.
The company's revenues fell as test orders from its primary customer dropped 22 percent, a trend it said is expected to continue.
In PNAS this week: optical mapping study of multiple myeloma, role for miR-204 in form of retinal dystrophy, and more.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.